Shares of Sienna Biopharmaceuticals Inc. (SNNA) are down over 20% in pre-market trading on Monday, following the failure of two of its pivotal acne trials with SNA-001.
from RTT - Top Story https://ift.tt/2LPJZfW
via IFTTT
from RTT - Top Story https://ift.tt/2LPJZfW
via IFTTT
Comments
Post a Comment